Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin – Yahoo Finance By Weight Loss Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin Yahoo Finance Why Novo Jumped — And Took Out Lilly And Viking Stocks Investor’s Business Daily Novo Nordisk shares pop on early-stage weight loss drug trial results CNBC Brought to you by Google News. Read the rest of the article here Facebook Twitter Pinterest